Entropy Neurodynamics (ASX:ENP) announced a milestone in its clinical trial investigating TRP-8803, an intravenous formulation of psilocin, for the treatment of binge eating disorder.
The company has completed the full enrolment of the first cohort in this trial, which is being conducted in partnership with Swinburne University.
The trial aims to recruit a total of 12 patients divided into two six-person cohorts to evaluate the safety, tolerability, and efficacy of the treatment alongside supportive therapy.
According to the update, "Cohort 1 recruitment complete with 6 patients enrolled in the study."
Within this group, two patients have already completed both dosing sessions, while the remaining four are currently in the baseline assessment phase or scheduled for their first infusion.
Early indicators appear promising, with the company noting that "Recruitment momentum follows clinically meaningful multi-domain improvements in patient outcomes observed in early patients."
The first patient treated demonstrated notable improvements at the four-week post-treatment mark.
Looking ahead, enrolment for the second cohort has already commenced, aiming to refine the therapeutic approach.
"Enrolment of patients for Cohort 2 is underway aiming to evaluate an optimised dose range," the report states. The patients will begin dosing after the completion of the protocol for Cohort 1.
ENP highlights that "TRP-8803's proprietary IV delivery approach continues to differentiate from oral psilocybin, supporting an improved scalability and precision dosing strategy."